Form 4: Protagenic Therapeutics Director Acquires Options in PTIX

Director Brian Corvese acquired options for 43,750 shares of Protagenic Therapeutics (PTIX) common stock at an exercise price of $1.74 on March 25, 2024.

Summary

• On March 25, 2024, Brian Corvese, a director of Protagenic Therapeutics, acquired options to purchase 43,750 shares of PTIX common stock.
• The exercise price for these options is $1.74 per share.
• The options vest monthly over 24 months, starting from the grant date, with full acceleration upon a change of control.
• The options expire on March 25, 2034.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of insider activity. The acquisition of options by a director can be seen as a mildly positive sign, but it's not a major event.

Positives

• A director's acquisition of options can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• Shareholders may view the director's option acquisition as a sign of confidence in the company's future.

Key Dates

Keywords

Protagenic Therapeutics, PTIX, Director, Options, Brian Corvese, Beneficial Ownership, SEC Form 4